<--- Back to Details
First PageDocument Content
Rhinology / General practice / Headaches / Sinusitis / Infectious diseases / Sinus / Common cold / Rhinorrhea / Paranasal sinuses / Medicine / Health / Human anatomy
Date: 2013-03-12 19:11:16
Rhinology
General practice
Headaches
Sinusitis
Infectious diseases
Sinus
Common cold
Rhinorrhea
Paranasal sinuses
Medicine
Health
Human anatomy

Staying healthy all year long These 6 tips can help: Antibiotics and your health

Add to Reading List

Source URL: www.nevadapublichealthfoundation.org

Download Document from Source Website

File Size: 244,35 KB

Share Document on Facebook

Similar Documents

What you need to know about… The paranasal sinuses are a group of air-filled cavities located in the facial area. The maxillary sinuses are located under

What you need to know about… The paranasal sinuses are a group of air-filled cavities located in the facial area. The maxillary sinuses are located under

DocID: 1ur9X - View Document

Intersect ENT Announces FDA Approval of Additional Indication for PROPEL® Mini Sinus Implant PROPEL Mini Now Indicated to Treat Patients With Frontal Sinus Disease MENLO PARK, Calif.—March 23, 2016—Intersect ENT, In

Intersect ENT Announces FDA Approval of Additional Indication for PROPEL® Mini Sinus Implant PROPEL Mini Now Indicated to Treat Patients With Frontal Sinus Disease MENLO PARK, Calif.—March 23, 2016—Intersect ENT, In

DocID: 1mCRC - View Document

Intersect ENT Announces Positive Preliminary Clinical Results for the PROPEL Mini Steroid Releasing Implant in Patients with Frontal Sinus Disease Menlo Park, Calif. – August 17, 2015 – Intersect ENT, Inc. (Nasdaq:XE

Intersect ENT Announces Positive Preliminary Clinical Results for the PROPEL Mini Steroid Releasing Implant in Patients with Frontal Sinus Disease Menlo Park, Calif. – August 17, 2015 – Intersect ENT, Inc. (Nasdaq:XE

DocID: 1lN0M - View Document

Intersect ENT Announces FDA Submission to Seek Expanded Indication of PROPEL Mini Steroid Releasing Implant to Treat Patients With Frontal Sinus Disease MENLO PARK, Calif.—September 29, 2015—Intersect ENT, Inc. (Nasd

Intersect ENT Announces FDA Submission to Seek Expanded Indication of PROPEL Mini Steroid Releasing Implant to Treat Patients With Frontal Sinus Disease MENLO PARK, Calif.—September 29, 2015—Intersect ENT, Inc. (Nasd

DocID: 1l9KI - View Document

Intersect ENT Announces Positive Clinical Results from Three Studies Evaluating Steroid Releasing Implants Placed in the Physician’s Office Menlo Park, Calif. and Dallas, Texas – September 28, 2015 – Intersect ENT,

Intersect ENT Announces Positive Clinical Results from Three Studies Evaluating Steroid Releasing Implants Placed in the Physician’s Office Menlo Park, Calif. and Dallas, Texas – September 28, 2015 – Intersect ENT,

DocID: 1kvXr - View Document